Business Combinations and Contingent Consideration (Tables)

12 Months Ended

Dec. 31, 2015

Talon Therapeutics, Inc. [Member]

Change in Fair Value of Contingent Consideration Related to Acquisition

Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisitions” in the accompanying Consolidated Statements of Operations.

	Fair Value of Talon CVR
December 31, 2014	$	2,379
Fair value adjustment for the year ended December 31, 2015	(1,002		)
December 31, 2015	$	1,377

Acquisition-Date Fair Value of Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following:

Cash consideration	$	3,000
Ligand Contingent Consideration	4,700
Total purchase consideration	$	7,700

Melphalan license [Member]

Change in Fair Value of Contingent Consideration Related to Acquisition

Adjustments to Ligand Contingent Consideration fair value are recognized within “change in fair value of the contingent consideration related to acquisitions” in the accompanying Consolidated Statements of Operations.

	Fair Value of Ligand Contingent Consideration
December 31, 2014	$	4,901
Fair value adjustment for year ended December 31, 2015	326
December 31, 2015	$	5,227

Summary of Allocation of Total Purchase Price to Net Assets Acquired

The allocation of the total purchase price to the net assets acquired is as follows:

IPR&D EVOMELA rights $ 7,700